These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37633797)

  • 21. Grape pomace reduces the severity of non-alcoholic hepatic steatosis and the development of steatohepatitis by improving insulin sensitivity and reducing ectopic fat deposition in mice.
    Daniel T; Ben-Shachar M; Drori E; Hamad S; Permyakova A; Ben-Cnaan E; Tam J; Kerem Z; Rosenzweig T
    J Nutr Biochem; 2021 Dec; 98():108867. PubMed ID: 34571189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
    Softic S; Cohen DE; Kahn CR
    Dig Dis Sci; 2016 May; 61(5):1282-93. PubMed ID: 26856717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathway-selective insulin resistance and metabolic disease: the importance of nutrient flux.
    Otero YF; Stafford JM; McGuinness OP
    J Biol Chem; 2014 Jul; 289(30):20462-9. PubMed ID: 24907277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats.
    Zhong Y; Li Z; Jin R; Yao Y; He S; Lei M; Wang X; Shi C; Gao L; Peng X
    Nutrients; 2022 Nov; 14(23):. PubMed ID: 36501024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload.
    Altamura S; Müdder K; Schlotterer A; Fleming T; Heidenreich E; Qiu R; Hammes HP; Nawroth P; Muckenthaler MU
    Mol Metab; 2021 Sep; 51():101235. PubMed ID: 33872860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis.
    Saponaro C; Gaggini M; Carli F; Gastaldelli A
    Nutrients; 2015 Nov; 7(11):9453-74. PubMed ID: 26580649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De novo lipogenesis in health and disease.
    Ameer F; Scandiuzzi L; Hasnain S; Kalbacher H; Zaidi N
    Metabolism; 2014 Jul; 63(7):895-902. PubMed ID: 24814684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease.
    Paglialunga S; Dehn CA
    Lipids Health Dis; 2016 Sep; 15(1):159. PubMed ID: 27640119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
    Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
    Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies.
    Yasin A; Nguyen M; Sidhu A; Majety P; Spitz J; Asgharpour A; Siddiqui MS; Sperling LS; Quyyumi AA; Mehta A
    Diabetes Res Clin Pract; 2024 May; 211():111650. PubMed ID: 38604447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism.
    Green CJ; Pramfalk C; Charlton CA; Gunn PJ; Cornfield T; Pavlides M; Karpe F; Hodson L
    BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32188593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reducing endogenous insulin is linked with protection against hepatic steatosis in mice.
    Akheruzzaman M; Hegde V; Shin AC; Dhurandhar NV
    Nutr Diabetes; 2020 Apr; 10(1):11. PubMed ID: 32286259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pu'erh tea extract-mediated protection against hepatosteatosis and insulin resistance in mice with diet-induced obesity is associated with the induction of de novo lipogenesis in visceral adipose tissue.
    Cai X; Hayashi S; Fang C; Hao S; Wang X; Nishiguchi S; Tsutsui H; Sheng J
    J Gastroenterol; 2017 Dec; 52(12):1240-1251. PubMed ID: 28364190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysregulation of hepatic metabolism with obesity: factors influencing glucose and lipid metabolism.
    Nagarajan SR; Cross E; Sanna F; Hodson L
    Proc Nutr Soc; 2022 Mar; 81(1):1-11. PubMed ID: 34726148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis.
    Pal SC; Méndez-Sánchez N
    World J Gastroenterol; 2023 Jul; 29(25):3999-4008. PubMed ID: 37476582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Martínez-Montoro JI; Balaguer-Román A; Murcia-García E; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez-Cáceres CM; Sledzinski T; Frutos MD; Hernández-Morante JJ; Fernández-García JC; Queipo-Ortuño MI; Ruiz-Alcaraz AJ; Mika A; Ramos-Molina B
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1781-1792. PubMed ID: 38217869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease.
    Colantoni A; Bucci T; Cocomello N; Angelico F; Ettorre E; Pastori D; Lip GYH; Del Ben M; Baratta F
    Cardiovasc Diabetol; 2024 May; 23(1):175. PubMed ID: 38769519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective association of fatty acids in the de novo lipogenesis pathway with risk of type 2 diabetes: the Cardiovascular Health Study.
    Ma W; Wu JH; Wang Q; Lemaitre RN; Mukamal KJ; Djoussé L; King IB; Song X; Biggs ML; Delaney JA; Kizer JR; Siscovick DS; Mozaffarian D
    Am J Clin Nutr; 2015 Jan; 101(1):153-63. PubMed ID: 25527759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fructose surges damage hepatic adenosyl-monophosphate-dependent kinase and lead to increased lipogenesis and hepatic insulin resistance.
    Gugliucci A
    Med Hypotheses; 2016 Aug; 93():87-92. PubMed ID: 27372863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.